Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis

BMC Medical Genetics

Ahmad A AlBoukai⁴  Adel Almogren¹  Zahid Shakoor¹  Joseph G Cal²  Esam H Alhamad³ 

[1]Departments of Pathology, King Saud University, Riyadh, Saudi Arabia

[2]Departments of Medicine, King Saud University, Riyadh, Saudi Arabia

[3]Pulmonary Division, Department of Medicine (38), College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia

[4]Departments of Radiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia

关键词: Cytokine;    Genotype;    Polymorphisms;    Idiopathic Pulmonary Fibrosis;   

Others  :  1137110
DOI  :  10.1186/1471-2350-14-66

 received in 2012-08-31, accepted in 2013-06-27,  发布年份 2013

【 摘 要 】

Background

Studies have demonstrated associations between cytokine gene polymorphisms and the risk of idiopathic pulmonary fibrosis (IPF). We therefore examined polymorphisms in the genes encoding interleukin (IL)-6, IL-10, interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and transforming growth factor-beta 1 (TGF-β₁), and compared the serum levels of these cytokines in IPF patients and healthy controls. Furthermore, we examined the association of the studied genotypes and serum cytokine levels with physiological parameters and the extent of parenchymal involvement determined by high-resolution computed tomography (HRCT).

Methods

Sixty patients with IPF and 150 healthy controls were included. Cytokine genotyping was performed using the polymerase chain reaction sequence specific primer (PCR-SSP) method. In a subset of patients and controls, serum cytokine levels were determined by enzyme-linked immunosorbent assay.

Results

There was no difference between IPF patients and controls in the genotype and allele distributions of polymorphisms in TNF-α, IFN-γ, IL-6, IL-10, and TGF-β₁ (all p > 0.05). The TNF-α (−308) GG, IL-6 (−174) GG and CG, and IL-10 (−1082, -819, -592) ACC ATA genotypes were significantly associated with HRCT scores (all p < 0.05). IL-10 (−1082, -819, -592) ACC haplotype was associated with the diffusion capacity of the lung for carbon monoxide, and ATA haplotype was associated with the partial pressure of oxygen (PaO₂) (all p < 0.05). The TGF-β₁ (codons 10 and 25) TC GG, TC GC, CC GG and CC GC genotypes were significantly associated with the PaO₂ and HRCT scores (p < 0.05). The TGF-β₁ (codons 10 and 25) CC GG genotype (5 patients) was significantly associated with higher PaO₂ value and less parenchymal involvement (i.e., a lower total extent score) compared to the other TGF-β₁ genotypes (81.5 ± 11.8 mm Hg vs. 67.4 ± 11.1 mm Hg, p = 0.009 and 5.60 ± 1.3 vs. 8.51 ± 2.9, p = 0.037, respectively). Significant differences were noted between patients (n = 38) and controls (n = 36) in the serum levels of IL-6 and IL-10 (both, p < 0.0001), but not in the levels of TNF-α and TGF-β₁ (both, p > 0.05).

Conclusion

The studied genotypes and alleles do not predispose to the development of IPF but appear to play an important role in disease severity. Our results suggest that the TGF-β₁ (codons 10 and 25) CC GG genotype could be a useful genetic marker for identifying a subset of IPF patients with a favorable prognosis; however, validation in a larger sample is required.

【 授权许可】

   
2013 Alhamad et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
• [2]Coker RK, Laurent GJ: Pulmonary fibrosis: cytokines in the balance. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1998, 11(6):1218-1221.
• [3]Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, et al.: Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000, 162(2 Pt 1):755-758.
• [4]Freeburn RW, Kendall H, Dobson L, Egan J, Simler NJ, Millar AB: The 3′ untranslated region of tumor necrosis factor-alpha is highly conserved in idiopathic pulmonary fibrosis (IPF). Eur Cytokine Netw 2001, 12(1):33-38.
• [5]Pantelidis P, Fanning GC, Wells AU, Welsh KI, Du Bois RM: Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 163(6):1432-1436.
• [6]Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV: Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J 2004, 34(3):126-129.
• [7]Vasakova M, Striz I, Slavcev A, Jandova S, Dutka J, Terl M, Kolesar L, Sulc J: Correlation of IL-1alpha and IL-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis. Scand J Immunol 2007, 65(3):265-270.
• [8]Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J: Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens 2006, 67(3):229-232.
• [9]Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Arias JM, Inigo P, Sanz S, et al.: Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168(4):431-435.
• [10]Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, et al.: High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005, 172(4):488-493.
• [11]Alhamad EH, Al-Kassimi FA, Alboukai AA, Raddaoui E, Al-Hajjaj MS, Hajjar W, Shaik SA: Comparison of three groups of patients with usual interstitial pneumonia. Respir Med 2012, 106(11):1575-1585.
• [12]American Thoracic S, European Respiratory S: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165(2):277-304.
• [13]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al.: Standardisation of spirometry. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2005, 26(2):319-338.
• [14]Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, et al.: Standardisation of the measurement of lung volumes. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2005, 26(3):511-522.
• [15]Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al.: Standardisation of the single-breath determination of carbon monoxide uptake in the lung. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2005, 26(4):720-735.
• [16]Alhamad EH, Al-Boukai AA, Al-Kassimi FA, Alfaleh HF, Alshamiri MQ, Alzeer AH, Al-Otair HA, Ibrahim GF, Shaik SA: Prediction of pulmonary hypertension in patients with or without interstitial lung disease: reliability of CT findings. Radiology 2011, 260(3):875-883.
• [17]Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med 2001, 345(7):517-525.
• [18]Furuie H, Yamasaki H, Suga M, Ando M: Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1997, 10(4):787-794.
• [19]Wallace WA, Ramage EA, Lamb D, Howie SE: A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995, 101(3):436-441.
• [20]Moore KW, de Waal MR, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
• [21]Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389(6652):737-742.
• [22]Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, et al.: Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 2000, 278(5):L914-L922.
• [23]Huaux F, Louahed J, Hudspith B, Meredith C, Delos M, Renauld JC, Lison D: Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol 1998, 18(1):51-59.
• [24]Martinez JA, King TE Jr, Brown K, Jennings CA, Borish L, Mortenson RL, Khan TZ, Bost TW, Riches DW: Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol 1997, 273(3 Pt 1):L676-L683.
• [25]Tsoutsou PG, Gourgoulianis KI, Petinaki E, Germenis A, Tsoutsou AG, Mpaka M, Efremidou S, Molyvdas PA: Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis. Respir Med 2006, 100(5):938-945.
• [26]Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265(3):621-636.
• [27]Akashi M, Loussararian AH, Adelman DC, Saito M, Koeffler HP: Role of lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation. J Clin Invest 1990, 85(1):121-129.
• [28]Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, Yamada W, Shiraishi Y, Hasegawa N, Fujishima S, et al.: Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008, 38(5):566-571.
• [29]Tabata C, Kadokawa Y, Tabata R, Takahashi M, Okoshi K, Sakai Y, Mishima M, Kubo H: All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(12):1352-1360.
• [30]Tsantes A, Tassiopoulos S, Papadhimitriou SI, Bonovas S, Kavalierou L, Vaiopoulos G, Meletis I: Suboptimal erythropoietic response to hypoxemia in idiopathic pulmonary fibrosis. Chest 2003, 124(2):548-553.
• [31]Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE Jr, Matthay MA, et al.: Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010, 299(1):L3-L7.
• [32]Ward PA, Hunninghake GW: Lung inflammation and fibrosis. Am J Respir Crit Care Med 1998, 157(4 Pt 2):S123-S129.
• [33]Khalil N, O’Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH: Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991, 5(2):155-162.
• [34]Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, Hance AJ, Tazi A: Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2003, 22(1):69-76.
• [35]Santana A, Saxena B, Noble NA, Gold LI, Marshall BC: Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1995, 13(1):34-44.
• [36]Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I: Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999, 104(1):5-11.
• [37]Li XX, Li N, Ban CJ, Zhu M, Xiao B, Dai HP: Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-beta1 and plasminogen activator inhibitor 1. Chin Med J 2011, 124(13):1923-1927.
• [38]Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD: Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999, 8(1):93-97.
• [39]Molina-Molina M, Lario S, Luburich P, Ramirez J, Carrion MT, Xaubet A: [Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis]. Arch Bronconeumol 2006, 42(8):380-383.
• [40]Yong SJ, Adlakha A, Limper AH: Circulating transforming growth factor-beta(1): a potential marker of disease activity during idiopathic pulmonary fibrosis. Chest 2001, 120(1 Suppl):68S-70S.
• [41]Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH: TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1997, 158(2):954-959.
• [42]Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN: Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993, 150(9):4188-4196.
• [43]Narayanan AS, Whithey J, Souza A, Raghu G: Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992, 101(5):1326-1331.
• [44]Majumdar S, Li D, Ansari T, Pantelidis P, Black CM, Gizycki M, du Bois RM, Jeffery PK: Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1999, 14(2):251-257.
• [45]Latsi P, Pantelidis P, Vassilakis D, Sato H, Welsh KI, du Bois RM: Analysis of IL-12 p40 subunit gene and IFN-gamma G5644A polymorphisms in Idiopathic Pulmonary Fibrosis. Respir Res 2003, 4:6. BioMed Central Full Text